Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Blood (2016) 128 (22): 55.

https://doi.org/10.1182/blood.V128.22.55.55

Published: 2016

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Margaret S. Lucas, PA-C, Nyla A. Heerema, PhD, Jennifer J. Matkovich, BS, Mollie E. Moran, CNP, Carolyn Cheney, BS, David M. Lucas, PhD, Donn C. Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2841.

https://doi.org/10.1182/blood.V108.11.2841.2841

Published: 2006

Journal Articles

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Thomas S. Lin, MD, PhD, Sabyasachi Biswas, PhD, Louie Naumovski, MD, PhD, Phillip Lecane, PhD, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Andrew P. Mone, MD, PhD, David M. Lucas, PhD, See-Chun Phan, MD, Richard A. Miller, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3486.

https://doi.org/10.1182/blood.V104.11.3486.3486

Published: 2004

Journal Articles

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

John C. Byrd, MD, Thomas S. Lin, MD, Phd, James T. Dalton, PhD, Di Wu, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, Kristie A. Blum, MD, Roshini S. Shank, BA, David M. Lucas, PhD, Margaret S. Lucas, PA-C, Jose-Ramon Suarez, MD, Michael R. Grever, MD

Blood (2004) 104 (11): 341.

https://doi.org/10.1182/blood.V104.11.341.341

Published: 2004

Journal Articles

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Jennifer Swenor, Margaret S. Lucas, PA-C, Mollie E. Moran, CRNP, Carolyn M. Cheney, MS, David M. Lucas, PhD, Donn Young, PhD, Michael A. Caligiuri, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 3469.

https://doi.org/10.1182/blood.V104.11.3469.3469

Published: 2004

Journal Articles

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, MSN, Mollie E. Moran, CRNP, David M. Lucas, PhD, Roshini S. Shank, BA, Eric H. Kraut, MD, Sheriff S. Farag, MD, PhD, Margaret S. Lucas, PA-C, Alexander D. Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2004) 104 (11): 2492.

https://doi.org/10.1182/blood.V104.11.2492.2492

Published: 2004

NARROW

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.

Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).

Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).

A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.

Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only